Atibuclimab (IC14), 20 mg/kg intravenously, once Clinical Trials

1 actively recruiting trial across 1 location

Filter by location:

St Louis, Missouri1 trial

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

Washington University School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.